Wockhardt gets expert panel nod for new antibiotic Zaynich; what it meansWockhardt gets expert panel nod for new antibiotic Zaynich; what it means

Introduction

Leading pharmaceutical company’s antibiotic Zaynich received favourable recommendation from CDSCO’s Subject Expert Committee for treating Gram-negative infections, advancing regulatory approval in India.

Also Read: East India Drums & Barrels shares price jumps after securing ₹4.6 Cr order from Indian Oil Corporation

Share price movement of Wockhardt

On March 30, 2026, Wockhardt Ltd opened at ₹1,185.00, down 0.34% from its previous close of ₹1,189.05. The stock reached a high of ₹1,231.30 (3.57%) and a low of ₹1,173.05. By 3:15 PM, it traded at ₹1,178.20, a 0.91% decrease, with a market cap of ₹19,144.05 crore.

Wockhardt’s Zaynich® Gets CDSCO Nod

Wockhardt Limited’s antibiotic, Zaynich® (Zidebactam/Cefepime), received a favourable recommendation from CDSCO’s Subject Expert Committee for marketing approval. The recommendation covers treatment of Gram-negative infections in India.

The approval follows review of non-clinical data, nine Phase 1 studies, a global Phase 3 study in cUTI/AP, a Phase 2 study in meropenem-resistant infections, and 85 compassionate-use cases.

Zaynich® was developed over 15 years by 150+ scientists. It demonstrated high clinical efficacy in real-world studies and compassionate-use cases, addressing multidrug-resistant and extensively drug-resistant Gram-negative infections globally.

Stock performance of Wockhardt for period of 1 week, 6 months, and 1 year

Wockhardt Ltd delivered a 1-week return of 8.11%, a 6-month return of -20.3%, and a 1-year return of -16.5%.

Also Read: Ceinsys Tech shares jump after securing multi-year ISRO deal worth ₹3.24 Cr

Shareholding pattern of Wockhardt

Particulars	Dec 2025	Sep 2025	Jun 2025
Promoter	49.10%	49.10%	49.10%
FII	7.00%	7.10%	7.30%
DII	10.60%	11.00%	11.00%
Public	33.40%	32.80%	32.60%

About Wockhardt

Wockhardt Ltd (NSE: WOCKPHARMA) is a global pharmaceutical and biotechnology company manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals, and topical products including creams and ointments.

Stay Ahead with the Latest Stock Market Updates – Click Here

Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time. The securities quoted are exemplary and are not recommendatory.

FAQs